Merck KGaA’s MET inhibitor, Tepotinib, received approval in Japan for #NSCLC yesterday, gaining a lead in the tight race against Capmatinib – Novartis’ MET inhibitor.

The two continue to strive for approval in the United States. #Kognitic‘s platform highlights the timeline for ongoing trials for both these drugs below. The approval for Tepotinib comes from Merck KGaA’s ongoing Vision trial.

#Oncology #Analytics #AI #Cancer #LungCancer #Data #Automated #Pharma #MachineLearning #Insights #CompetitiveEdge #DataDriven